Cy5.5 maleimide (non-sulfonated)
| 规格 | 价格 | 货期 | 数量 |
|---|---|---|---|
| 5mg | ¥6949.00 ¥4864.30 | 现货 | |
| 25mg | ¥13642.00 ¥9549.40 | 现货 |
特色产品
- 用于免疫印迹和质谱分析等后续操作
- 适用于30 KDa-130 KDa大小的蛋白
- 可将信号灵敏度提高100倍
- 同时保持稳定的特异性和分辨率
- 提供更高的转录效率并抑制免疫激活
- 使用5-moUTP和Cy5-utp修饰
产品描述
Cy5.5 maleimide is a thiol reactive dye which is capable of selective labeling of proteins which contain sulfhydryl groups. Cy5.5 maleimide has near infrared emission that makes it suitable for bioimaging applications. This reagent can replace Alexa Fluor 680 and DyLight 680. For biomolecule labeling, the labeling reagent has low aqueous solubility, using of organic co-solvent to dissolve this molecular is necessary for efficient reaction. First, Cyanine dye should be dissolved in organic solvent and then added to a solution of biomolecule in appropriate aqueous buffer.
Cy5.5-NLP conjugate was synthesized by the NLP peptide and the Cy5.5-maleimide in 100 μL of anhydrous DMF, to which 10 μL of DIPEA was added. In the Her2/neu positive (SKBR-3 and BT474) or Her2/neunegative (MDA-MB-231) breast cancer cells, intracellular localization of Cy5.5-labeled peptide conjugates make the effects visible [1].
Reference:
[1]Cai, H. ; Singh, A.N.; Sun, X.; Peng, F. Synthesis and Characterization of Her2-NLP Peptide Conjugates Targeting Circulating Breast Cancer Cells: Cellular Uptake and Localization by Fluorescent Microscopic Imaging. Journal of Fluorescence, 2015, 25(1), 113–117.
产品性质
| 物理外观 | A solid |
| 分子式 | C46H49ClN4O3 |
| 分子量 | 741.36 |
| 化学名称 | 6-[(2E)-1,1-dimethyl-2-[(2E,4E)-5-(1,1,3-trimethylbenzo[e]indol-3-ium-2-yl)penta-2,4-dienylidene]benzo[e]indol-3-yl]-N-[2-(2,5-dioxopyrrol-1-yl)ethyl]hexanamide |
| 溶解度 | ≥74.1 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH |
| SMILES | CC(/C1=C\C=C\C=C\C(C(C)2C)=[N+](C3=C2C4=CC=CC=C4C=C3)CCCCC/C([O-])=N/CCN5C(C=CC5=O)=O)(C6=C(N1C)C=CC7=CC=CC=C76)C.Cl |
| 存储条件 | -20°C干燥避光 |
| 运输条件 | 蓝冰 |
| 最大发射波长 | 710nm |
| 最大激发波长 | 684nm |
生物相关数据
质量控制
APExBIO 顾客使用本产品发表的 1 篇科研文献
- 1. Longkun Wang, Chunqian Zhao, et al. "Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer." Int J Mol Sci. 2023 Feb 28;24(5):4646. PMID: 36902076



沪公网安备 31011002003500